Healthcare stocks have been in the spotlight recently, with President Trump’s healthcare-focused executive order bringing a win for the sector. The order directed the health department to collaborate with Congress to revamp a law allowing Medicare to negotiate prescription drug prices, a change that pharmaceutical companies have long lobbied for. While the negotiation process is included in legislation, Trump’s executive order cannot implement the change itself, but it directs the Secretary of Health and Human Services to work with Congress to make the necessary changes.
According to CNBC, drug makers have been working to delay the eligibility timeline for small-molecule drugs to be available for price negotiations by four years, including pills and most medications. This delay aligns with the current 13-year wait for more complex biotech drugs to be eligible for Medicare price negotiations.
Trump’s executive order also aims to slash healthcare costs, following a national security report on the pharma industry. This report has been seen as a precursor to potential sector-specific tariffs.
Medicare’s negotiating powers have been a topic of debate, with drug makers expressing concerns about potential impacts on innovation. The current law allows the government to negotiate prices for drugs with no competition, including complex biotech or biologic medications after 13 years on the market, or 9 years for their administration as capsules and pills.
While specifics were not provided, White House officials mentioned that other changes to the negotiation process could yield more savings than those achieved during the first round under the Biden administration. This includes negotiating prices for 15 medications, such as Pfizer’s cancer drugs and Novo Nordisk’s diabetes and weight-loss treatments.
Alignment Healthcare, Inc. (NASDAQ:ALHC) is a key player in the healthcare sector, offering personalized healthcare solutions through its Medicare Advantage plans. The company has seen positive financials in its latest earnings report, with a significant increase in revenue and Medicare Advantage membership.
In a recent report, Whit Mayo from Leerink Partners reiterated a Buy rating on Alignment Healthcare, Inc. and set a price target of $20.00. The company’s strong financial performance and growth in key performance indicators have boosted investor sentiment.
While ALHC ranks 11th on the list of best performing healthcare stocks to buy now, there are other opportunities in the market, particularly in the AI sector. Some AI stocks show greater promise for delivering higher returns within a shorter time frame. If you are interested in exploring AI stocks with significant potential, consider checking out our report on the cheapest AI stock poised for massive gains.
In conclusion, healthcare stocks continue to be a focus for investors, with potential opportunities for growth and profitability. Stay informed about the latest developments in the sector to make informed investment decisions.
